Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance.
Drug resistance
RNA interference
cancer
gene silencing
post-transcriptional gene
treatment-resistant
cancers.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
01
2018
revised:
10
03
2018
accepted:
29
03
2018
pubmed:
4
4
2018
medline:
27
12
2019
entrez:
4
4
2018
Statut:
ppublish
Résumé
RNAi, post-transcriptional gene silencing mechanism, could be considered as one of the most important breakthroughs and rapidly growing fields in science. Researchers are trying to use this discovery in the treatment of various diseases and cancer is one of them although there are multiple treatment procedures for treatment-resistant cancers, eradication of resistance remain as an unsolvable problem yet. The current review summarizes both transcriptional and post-transcriptional gene silencing mechanisms, and highlights mechanisms leading to drug-resistance such as, drug efflux, drug inactivation, drug target alteration, DNA damages repair, and the epithelial-mesenchymal transition, as well as the role of tumor cell heterogeneity and tumor microenvironment, involving genes in these processes. It ultimately points out the obstacles of RNAi application for in vivo treatment of diseases and progressions that have been achieved in this field.
Identifiants
pubmed: 29611475
pii: CMC-EPUB-89483
doi: 10.2174/0929867325666180403141554
doi:
Substances chimiques
ATP-Binding Cassette Transporters
0
RNA, Catalytic
0
RNA, Small Interfering
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6282-6303Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.